Cancer, Cancer Treatment

Gemin Xsecured a patent from the U.S. Patent and Trademark Office protecting the composition of matter of Obatoclax, its lead new drug candidate, through 2025.

Obatoclax is an experimental oncology treatment based on programmed cell death — a process known as apoptosis.

The new drug candidate, according to Gemin X, has the potential to be a “first-in-class pan Bcl-2 inhibitor,” which is a drug that blocks pathways used by Bcl-2 proteins that regulate apoptosis. Researchers have found the overexpression of Bcl-2 protein enhances the potential of cancer cells to metastasize. Obatoclax is in mid-stage clinical testing for the treatment of elderly acute myeloid leukemia and the treatment of small-cell lung cancer.

“This key patent is core to our overall [intellectual property] strategy and provides important protection for our Obatoclax program,” said Dr. Glenn J. Gormley, the company’s president and CEO.

Source

--------------------------------------------------------------------------------------------
Related Posts:


A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the U.S. Food and Drug Administration for Phase I clinical trials. Generally, only five potential anticancer drugs out of every 5,000 to 10,000 developed are approved by the FDA for Phase

Full Post: Speedy FDA approval puts Stehlin anticancer drug in clinical trials
--------------------------------------------------------------------------------------------

SUNDAY, Oct. 19 — Ovarian cancer is one of the most difficult cancers to diagnose, making it one of the most lethal. The ovaries aren’t easily accessible for examination, unlike a woman’s skin or breast or cervix. And the symptoms that accompany ovarian cancer are vague and can be confused with other less life-threatening conditions. “A lot

Full Post: Small Victories in the War Against Ovarian Cancer
--------------------------------------------------------------------------------------------

The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation’s unique drug product for children with Ewing’s Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers

Full Post: FDA grants orphan drug status to new ‘Trojan Horse’ like Ewing’s Sarcoma drug
--------------------------------------------------------------------------------------------

(Ivanhoe Newswire) — Death rates from cervical cancer have dropped dramatically over the past decades due to the Pap test and now a new test could help doctors identify cancer even earlier. Researchers say by using high-resolution magnetic resonance imaging (MRI), they get better imaging of smaller tumors. The study included 59 women between 24

Full Post: Cervical Cancer Spotted Earlier
--------------------------------------------------------------------------------------------

Do you know that breast cancer is the most common cancer among women? Breast cancer is also the second leading cause of cancer related deaths in American women. Most cases of breast cancer are diagnosed when a mammogram reveals a lump. A change in the texture of breast tissue can also be a warning sign

Full Post: Nolvadex PCT